These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration. Nightingale SL J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959 [TBL] [Abstract][Full Text] [Related]
23. Health and Human Services policy for protection of human subjects research--HHS. Final rule. Fed Regist; 1994 Jun; 59(104):28276. PubMed ID: 10135123 [TBL] [Abstract][Full Text] [Related]
24. Harmonizing regulations for biomedical research: a critical analysis of the US and Venezuelan systems. Di Tillio-Gonzalez D; Fischbach RL Dev World Bioeth; 2008 Dec; 8(3):167-77. PubMed ID: 17488491 [TBL] [Abstract][Full Text] [Related]
25. Just-in-time IRB review: capitalizing on scientific merit review to improve human subjects research compliance. Kelly PA; Johnson ML IRB; 2005; 27(2):6-10. PubMed ID: 15948325 [No Abstract] [Full Text] [Related]
26. [Codes of ethics for nursing research]. Lanara B Noseleutike; 1989; 130(28):247-56. PubMed ID: 2627247 [TBL] [Abstract][Full Text] [Related]
27. Public health practice vs research: implications for preparedness and disaster research review by State Health Department IRBs. Perlman D Disaster Med Public Health Prep; 2008 Oct; 2(3):185-91. PubMed ID: 18845930 [TBL] [Abstract][Full Text] [Related]
28. Protecting human subjects in research. Orticio LP Insight; 2009; 34(3):14-6. PubMed ID: 19708428 [TBL] [Abstract][Full Text] [Related]
29. Evolution, structure and function of the institutional review board. Prentice ED; Zetterman RK Nebr Med J; 1983 Sep; 68(9):293-5. PubMed ID: 6633743 [No Abstract] [Full Text] [Related]
31. [Ethics review committees for human research: the challenge of strengthening this process in Colombia]. Miranda MC; Palma GI; Jaramillo E Biomedica; 2006 Mar; 26(1):138-44. PubMed ID: 16929911 [TBL] [Abstract][Full Text] [Related]
32. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration. Bramstedt KA; Kassimatis K Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112 [TBL] [Abstract][Full Text] [Related]
33. PSRO: the pharmacist's role in the review process. Knoben JE Hosp Formul; 1975 Jun; 10(6):287-8. PubMed ID: 10273082 [No Abstract] [Full Text] [Related]
34. The pharmacist as an active member of the institutional review board. Mutnick AH; Miller LS Top Hosp Pharm Manage; 1993 Apr; 13(1):55-7. PubMed ID: 10128793 [No Abstract] [Full Text] [Related]
35. DHHS human subjects protection: the new regulations revisited. Grunder TM Health Matrix; 1983; 1(2):37-41. PubMed ID: 10263330 [TBL] [Abstract][Full Text] [Related]
36. Institutional review board consideration of chart reviews, case reports, and observational studies. Neff MJ Respir Care; 2008 Oct; 53(10):1350-3. PubMed ID: 18811999 [TBL] [Abstract][Full Text] [Related]